Understanding the essentials of drug interactions: A potential need for safe and effective use of drugs

Kathmandu University Medical Journal

Volumn 5, Issue 19, 2007, Pages 421-430

  Bista, Durga ^a   Palaian, S ^a   Shankar, P R ^b   Prabhu, M M ^a   Paudel, R ^a   Mishra, P ^a  

^a MANIPAL COLLEGE OF MEDICAL SCIENCES   (Nepal)

^b KASTURBA HOSPITAL   (India)

Author keywords

Drug interaction; Drug interaction monitoring; Herbal drug interactions; Over the counter medications

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTACID AGENT; ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; CARBAMAZEPINE; CHELATING AGENT; CIPROFLOXACIN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GARLIC EXTRACT; GINGER EXTRACT; GINKGO BILOBA EXTRACT; GINSENG EXTRACT; GLIBENCLAMIDE; HYPERICUM PERFORATUM EXTRACT; MACROLIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PARACETAMOL; POTASSIUM DERIVATIVE; QUINIDINE; QUINOLONE DERIVATIVE; SIMVASTATIN; SPIRONOLACTONE; SULFAMETHOXAZOLE; SULFONYLUREA DERIVATIVE; THEOPHYLLINE; UNINDEXED DRUG; WARFARIN;

BLEEDING; DRUG ANTAGONISM; DRUG EFFECT; DRUG EFFICACY; DRUG MONITORING; DRUG POTENTIATION; DRUG SAFETY; GASTROINTESTINAL HEMORRHAGE; HERB DRUG INTERACTION; HUMAN; HYPOGLYCEMIA; REVIEW;

EID: 41849114579     PISSN: 18122027     EISSN: 18122078     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Sandson N. Drug-drug interaction: the silent epidemic. Psychiatric Services 2005; 56(1): 22-4.
2. Hartshorn EA. Evolution of drug-drug interactions: a personal viewpoint. Ann Pharmacother 2006; 40: 112-3.
3. Stockley I H. Drug interaction: a source book of adverse interaction, their mechanisms, clinical importance and management. 5th ed. Pharmaceutical Press, London 1999.
4. Lee A, Stockley IH. Drug interactions In Walker R, Edwards C. Clinical Pharmacy and Therapeutics. 3rd edition. Churchill Livingstone, Philadelphia 2003: 21-31.
5. Gosney M, Tallis R. Prescription of contraindicated and interacting drugs in elderly patients admitted to hospital. Lancet 1984; 1: 564-7
6. Kinney E. Expert system detection of drug interactions: results in consecutive patients. Comput Biomed Res 1986; 19: 462-7.
7. Dambro MR, Kallgren MA. Drug interaction in a clinic using COSTER. Comput Biol Med 1988; 18:31-8,
8. Shinn AF, Shrewsbury RP, Anderson KW. Development of a computerized drug database (MEDICOM) for use in a patient specific environment. Drug Inf J 1983; 17:205-10.
9. Classen DC, Pestotnick SL, Evans RS, Burke JP. Computer surveillance of adverse drug events in hospital patients. JAMA 1991; 266: 2847-51.
10. Jankel C A, Fitterman L K. Epidemiology of drug-drug interactions as a cause of hospital admissions. Drug safety 1993; 9 (1): 55-9.
11. Leape L, Brennam T A, Laired N et al. The nature of adverse events in hospitalized patients: results of the Harvard Medical Practice Study II. N Engl J Med 1992; 324: 377-84.
12. Boston Collaborative Drug Surveillance Program: Adverse drug interactions. JAMA 1972; 220: 1238-9
13. Brown CH. Overview of drug interactions. US Pharm 2000; 25: HS3- HS30.
14. Hussar DA. Drug interaction. In: Gennaro, Marderosian AHD, Hanson GR et al. Remington The science and practice pf pharmacy. Philadelphia: Lippincott Williams and Willinks; 2000: P: 1746-61.
15. Thomas A, Routledge PA. Drug interaction in clinical practice. Focus. Quarterly bulletin of pharmacovigilance. May 2003
16. Shankar PR, Partha P, Nagesh S. Prescribing patterns in medical outpatients. Int J Clin Pract 2002; 56: 549-1.
17. Joshi MP, Sugimoto T, Santoso B. Geriatric prescribing in the medical wards of a teaching hospital in Nepal. Pharmacoepidemiol Drug Saf 1997; 6: 417-21.
18. Smith J W, Seild L G, Cluff L E. Studies on the epidemiology of adverse drug reactions. V. Clinical factors influencing susceptibility. Ann Intern Med 1969; 65: 629.
19. Lambrecht JE, Hamilton W, Rabinovich A. A Review of Herb-Drug Interactions: Documented and Theoretical. US Pharmacist 2000; 25 (8):42-53.
20. Cupp MJ. Herbal Remedies: adverse effects and drug interactions. Am Fam Physician 1999; 59(5): 1239-45.
21. Vuksan V, Stavro SP, Sievenpiper JL et al. Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes. Diabetes Care 2000; 23(9): 1221-26.
22. Legnani C, Frascaro M, Gauzzaloca G et al. Effects of a dried garlic preparation on fibrinolysis and platelet aggregation in healthy subjects. Arzneimittelforschung 1993; 43(2): 119-22.
23. Hennessy M, Kelleher D, Spiers JP et al. St. John's Wort increases expression of P-glycoprotein: implications for drug interactions. Br J Clin Pharmacol 2002; 53(1): 75-82.
24. Kruth P, Brosi E, Fux R et al. Ginger-associated overanticoagulation by phenprocoumon. Ann Pharmacother 2004; 38: 257-60.
25. Meisel C, Johne A, Roots I. Fatal intracerebral mass bleeding associated with Ginkgo biloba and ibuprofen. Atherosclerosis 2003; 167(2): 367.
26. Sikka R, Magauran B, Ulrich A, Shannon M. Bench to bedside: Pharmacogenomics, adverse drug interactions, and the Cytochrome P450 system. Acad Emerg Med 2005; 12(12): 1227-35.
27. Brosen K. Recent developments in hepatic drug oxidation: implications for clinical pharmacokinetics. Clin Pharmacokinet 1990;18: 220-39.
28. Beers MH, Berkow R. The Merck manual of diagnosis and therapy. 17th edition. New Jersy: Merck research laboratories; 1999.
29. Chan TYK. Adverse interactions between warfarin and nonsteroidal antiinflammatory drugs: mechanisms, clinical significance, and avoidance. Ann Pharmacother 1995; 29:1274-83.
30. Hassall C, Feetam CL, Leach RH et al. Potentiation of warfarin by co-trimoxazole (letter). Lancet 1975; 2: 1155.
31. Schwartz J, Bachmann K, Perrigo E. Interaction between warfarin and erythromycin. South Med J 1983; 76: 91-3.
32. Zielinski JJ, Haidukewych D. Dual effects of carbamazepine-phenytoin interaction. Ther Drug Monit 1987; 9: 21-3.
33. Hansten PD. Interactions between anticonvulsant drugs: primidone, diphenylhydantoin and phenobarbital. Northwest Med J 1974; 1: 17.
34. Chan TYK, Critchley JAJH. Life-threatening hyperkalaemia in an elderly patient receiving captopril, furosemide (frusemide) and potassium supplements. Drug Safety 1992; 7: 159-61.
35. Anon. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study (RALES)). Am J Cardiol 1996; 78: 902-7.
36. Product Information: Lanoxicaps(R), digoxin. GlaxoSmithKline, Research Triangle Park, NC, 10/2003.
37. Pedersen KE, Thayssen P, Klitgaard NA et al. Influence of verapamil on the inotropism and pharmacokinetics of digoxin. Eur J Clin Pharmacol 1983; 25: 199-206.
38. Kuback R, Antal E, Juhl R et al. Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects. Ann Pharmacother 1996; 30: 20-6.
39. Wijnands WJA, Vree TB, Baars AM et al. Steady state kinetics of the quinolone derivatives ofloxacin, enoxacin, ciprofloxacin, and perfloxacin during maintenance treatment with theophylline. Drugs 1987; 34 (suppl 1): 159-69.
40. Sutfin T, Balmer K, Bostrom H et al. Stereoselective interaction of omeprazole with warfarin in healthy men. Ther Drug Monit 1989; 11: 176-84.
41. Mason P. Food and medicines. Pharmaceutical Journal 2002; 269:571-3.
42. Leon AS, Spiegel HE, Thomas G et al. Pyridoxine antagonism of levodopa in parkinsonism. JAMA 1971; 218: 1924 -7.
43. Jusko WJ. Influence of cigarette smoking on drug metabolism in man. Drug Metab Rev 1979; 9: 221-36.
44. Kafle KK, Madden JM, Shrestha AD et al. Can licensed drug sellers contribute to safe motherhood? A survey of the treatment of pregnancy related anemia in Nepal. Soc Sci Med 1996; 42: 1577-88.
45. Brackett CC, Bloch JD. Phenytoin as a possible cause of acetaminophen hepatotoxicity: case report and review of the literature. Pharmacotherapy 2000; 20: 229-33.
46. Richman DD, Fischl MA, Grieco MH et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo-controlled trial. N Engl J Med 1987; 317: 192-7.
47. Epstein MM, Nelson SD, Slattery JT et al. Inhibition of the metabolism of paracetamol by isoniazid. Br J Clin Pharmacol 1991; 31: 139-42.
48. Catella-Lawson F, Reilly MP, Kapoor SC et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. New Engl J Med 2001; 345(25): 1809-17.
49. Yett HS, Skillman JJ, Salzman EW. The hazards of aspirin plus heparin (letter). N Engl J Med 1978; 298: 1092.
50. Guazzi MD, Campodonico J, Celeste F et al. Antihypertensive efficacy of angiotensin converting enzyme inhibition and aspirin combination. Clin Pharmacol Ther 1998; 63:79-86.
51. Cassano WF. Serious methotrexate toxicity caused by interaction with ibuprofen (letter). Am J Pediatr Hematol Oncol 1989; 11: 481-2.
52. Jarosinski PF, Moscow JA, Alexander MS et al. Altered phenytoin clearance during intensive chemotherapy for acute lymphoblastic leukemia. J Pediatr 1988; 112: 996-9.
53. Oosterhuis B, Jonkman JH, Andersson T et al. Minor effect of multiple dose omeprazole on the pharmacokinetics of digoxin after a single oral dose. Br J Clin Pharmacol 1991; 32: 569-72.
54. Product Information: Prilosec(R), omeprazole. Astra Merck Inc., Wayne, PA, 1997.
55. Product Information: Prilosec(R), omeprazole. Astra Merck Inc., Wayne, PA, 1995.
56. Lelawongs P, Barone JA, Colaizzi JL et al. Effect of food and gastric acidity on absorption of orally administered ketoconazole. Clin Pharm 1988; 7:228-35.
57. Product Information: Avandamet(TM), rosiglitazone maleate and metformin hydrochloride. GlaxoSmithKline, Research Triangle Park, NC, 11/2003.
58. Fernandes E, Melewicz FM. Ranitidine and theophylline (letter). Ann Intern Med 1984; 100: 459.
59. USFDA. Drug Interactions: What You Should Know. Available on http://www.fda.gov/cder/consumerinfo/druginteractions.htm (Accessed last on 27th March 2006).